Seven Things FDA Already Knew About Your Company Before They Pulled Into Your Parking Lot

7 Things FDA Already Knew About Your Company Before They Pulled Into Your Parking Lot

Written by a former FDA Investigator who spent 14 years issuing Form FDA-483s, then 13 years on the other side of the table as a pharmaceutical quality executive, including work navigating J&J out of consent decree.

Your next FDA inspection does not start when the Investigator walks into your conference room. It starts weeks earlier, at a desk, while they review everything the agency already has on your company. And in 2026, that review is faster and more comprehensive than most quality teams realize.

[This is an employer-reimbursable professional compliance resource. Send this page to your Quality Director, Site Head, Regulatory Affairs leader or Learning and Development department for approval.]

This document breaks down the seven things FDA already knows before a single Investigator sets foot on your property:

• Why your complete inspection history, including every prior commitment your company made and whether you actually kept it, is the foundation of the Investigator's working theory before they arrive
• Why a Warning Letter at any facility in your corporate family, not just your own site, changes how your inspection is conducted
• How your own Field Alert Reports and recalls function as admissions FDA reads for pattern, not just paperwork
• How the agency compares marketplace complaints and adverse event data against your internal complaint records, and why the gap between the two is where serious findings come from
• Why an anonymous tip from inside your own walls may already be shaping the inspection before you know it started, and what that says about your internal speak-up culture
• A detailed, non-hyped look at Elsa, FDA's internal AI tool now integrated with the agency's consolidated HALO data platform, what the agency says it uses it for, and the real risk of AI-generated inferences shaping your inspection before a human fully verifies them
• Why knowing the classification of your inspection (routine, for-cause, or compliance follow-up) tells you more about what is about to happen than almost anything else

Each section includes a first-person Investigator's Perspective, a clear "what this means for you" action item, and specific guidance your quality team can use to close the gap between what FDA already knows and what you know about your own facility.

By the time the Investigator introduces themselves, the theory is already built. This document tells you what that theory is made of, so you can walk in knowing your own facility at least as well as they do.

For informational purposes only. Does not constitute legal advice.